Merus (MRUS) Stock Rating Upgraded by BidaskClub

Merus (NASDAQ:MRUS) was upgraded by equities researchers at BidaskClub from a “strong sell” rating to a “sell” rating in a report released on Wednesday.

Other equities research analysts also recently issued reports about the stock. ValuEngine downgraded shares of Merus from a “buy” rating to a “hold” rating in a research note on Monday, September 24th. Zacks Investment Research downgraded shares of Merus from a “buy” rating to a “hold” rating in a research note on Friday, November 9th.

Shares of NASDAQ:MRUS opened at $14.39 on Wednesday. Merus has a 52-week low of $11.00 and a 52-week high of $26.74.



A number of large investors have recently modified their holdings of MRUS. Aquilo Capital Management LLC lifted its position in Merus by 3.6% during the third quarter. Aquilo Capital Management LLC now owns 1,295,713 shares of the biotechnology company’s stock worth $25,577,000 after acquiring an additional 44,799 shares during the last quarter. Laurion Capital Management LP acquired a new stake in Merus during the third quarter worth approximately $2,104,000. Morgan Stanley lifted its position in Merus by 74.3% during the third quarter. Morgan Stanley now owns 71,643 shares of the biotechnology company’s stock worth $1,415,000 after acquiring an additional 30,538 shares during the last quarter. Renaissance Technologies LLC lifted its position in Merus by 26.8% during the second quarter. Renaissance Technologies LLC now owns 48,200 shares of the biotechnology company’s stock worth $1,097,000 after acquiring an additional 10,200 shares during the last quarter. Finally, Acadian Asset Management LLC acquired a new stake in Merus during the third quarter worth approximately $537,000. Institutional investors and hedge funds own 53.32% of the company’s stock.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its bispecific antibody candidate pipeline includes MCLA-128, which is in a Phase II clinical trial for the treatment of patients with metastatic breast cancer; and Phase I/II study for treating gastric, ovarian, endometrial, and non-small cell lung cancers.

Read More: What are no-load funds?

Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply